Literature DB >> 9400593

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.

M W Carroll1, B Moss.   

Abstract

Modified vaccinia virus Ankara (MVA), attenuated by over 500 passages in primary chick embryo fibroblasts (CEF), is presently being used as a safe expression vector. We compared the host ranges of MVA and the parental Ankara strain in CEF and 15 permanent cell lines. The cells could be grouped into three categories: permissive, semipermissive, and nonpermissive. For MVA, the permissive category consisted of primary CEF, a quail cell line derived from QT6, and the Syrian hamster cell line BHK-21. Only in BHK-21 cells did the virus yield approach that occurring in primary CEF. The semipermissive category included two African green monkey cell lines: BS-C-1 and CV-1. The nonpermissive category for MVA consisted of three human cell lines HeLa, 293, and SW 839; one rhesus monkey cell line FRhK-4; two Chinese hamster cell lines CHO and CHL; one pig cell line PK(15); and three rabbit cell lines RK13, RAB-9, and SIRC. The grouping for MVA with a restored K1L host range gene was similar except for the inclusion of RK13 cells among permissive lines. The grouping for the Ankara strain, however, was quite different with more permissive and semipermissive cell lines. Nevertheless, in cells that were permissive for MVA, the virus replicated to higher levels than Ankara, consistent with both positive and negative growth elements associated with the adaptation of MVA. The cell lines were also characterized according to their susceptibility to MVA-induced cytopathic effects, expression of a late promoter regulated reporter gene by an MVA recombinant, and stage at which virion morphogenesis was blocked. Finally, the permissive BHK-21 cell line was shown to be competent for constructing and propagating recombinant MVA, providing an alternative to primary CEF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400593     DOI: 10.1006/viro.1997.8845

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  135 in total

1.  Identification of human herpesvirus 8-specific cytotoxic T-cell responses.

Authors:  M Osman; T Kubo; J Gill; F Neipel; M Becker; G Smith; R Weiss; B Gazzard; C Boshoff; F Gotch
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

3.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

5.  Protein products of the open reading frames encoding nonstructural proteins of human astrovirus serotype 8.

Authors:  Ernesto Méndez; M P Elizabeth Salas-Ocampo; María Elena Munguía; Carlos F Arias
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Increased readthrough transcription across the simian virus 5 M-F gene junction leads to growth defects and a global inhibition of viral mRNA synthesis.

Authors:  G D Parks; K R Ward; J C Rassa
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus.

Authors:  Justin J Pollara; April H Spesock; David J Pickup; Scott M Laster; Ian T D Petty
Journal:  Virology       Date:  2012-04-23       Impact factor: 3.616

9.  Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells.

Authors:  Juan Carlos Gallego-Gómez; Cristina Risco; Dolores Rodríguez; Pilar Cabezas; Susana Guerra; José L Carrascosa; Mariano Esteban
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.

Authors:  Melissa R Ryerson; Monique M Richards; Marc Kvansakul; Christine J Hawkins; Joanna L Shisler
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.